What’s new

• Consolidated revenue climbed to ₹14,059 lacs from ₹12,075 lacs.
• Standalone results show a net loss of ₹172 lacs against a prior-year profit of ₹464 lacs.
• The chemical manufacturing subsidiary delivered profit growth, offsetting pharmaceutical losses.

Why it matters

The company's performance is bifurcated between a profitable chemical manufacturing unit and a struggling pharmaceutical business. The standalone loss is largely a result of the absence of one-time asset sale gains that boosted the previous year's figures.

What we’re watching

• Any turnaround plans for the loss-making pharmaceutical segment.
• Whether the chemical manufacturing subsidiary can sustain its growth trajectory.
• Future margin trends as the company balances its two distinct business lines.

The full read

Makers Laboratories closed FY26 with a consolidated profit of ₹235 lacs, down from ₹749 lacs the year prior. Revenue grew to ₹14,059 lacs from ₹12,075 lacs.

Performance is bifurcated. While the chemical manufacturing subsidiary, Resonance Specialties, posted strong profit growth, the pharmaceutical business remained stubbornly loss-making throughout the period. On a standalone basis, the company reported a net loss of ₹172 lacs compared to a ₹464 lacs profit in FY25. This standalone decline is largely attributed to the absence of a one-time gain from an asset sale that occurred in the previous fiscal year. The auditor provided an unmodified opinion on the results. This disclosure follows standard reporting expectations and contains no surprises beyond established quarterly trends. The pharmaceutical segment is the clear drag on the group's bottom line.

Primary source: BSE · NSE